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We investigated prostate cancer incidence in East Anglia from 1971to 2000. Using age-period-cohort modelling, the number of cases
expected in 1991–2000, based on pre-PSA trends, 1971–1990, was compared with that observed. Based on pre-1991 trends, 9203
new cases were expected in 1991–2000, but 9788 cases were observed, an excess of 6%.
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Prostate cancer is now the most frequently diagnosed cancer in
men in the UK. Worldwide, prostate cancer has been diagnosed
with increasing frequency over the recent decades (Coleman et al,
1993). The extent to which the observed increase represents an
increase in the inception of the disease as opposed to an artefact of
increased detection remains debatable.
In the UK, prostate-specific antigen (PSA) testing became
generally available in 1991 but has not been recommended for
mass screening. Ad hoc case finding by PSA testing, and increased
PSA testing of men who present with lower urinary tract symptoms
(LUTS), both have the capacity to inflate registration rates for
prostate cancer. In men, the prevalence of urological symptoms
increases with age and the increased availability of PSA testing
may be leading to diagnosis of prostate cancer which either would
not have arisen clinically or would not have come to clinical
attention later in life.
This study of the incidence of prostate cancer in the three
counties of Norfolk, Suffolk and Cambridgeshire (NSC) between
1971 and 2000, sought to assess the effect of PSA testing on
prostate cancer registrations during the 1990s.
MATERIALS AND METHODS
Extracts from the records of all men resident in NSC with prostate
cancer diagnosed from 1/1/1971 to 31/12/2000 were obtained from
the Eastern Cancer Registry and Information Centre (ECRIC).
Mid-year population estimates for the three counties for each year
from 1971 to 2000, stratified by sex and age were obtained from the
Office of National Statistics (ONS).
Age-specific and age-standardised incidence rates (using direct
standardisation and the European Standard Population) were
calculated for each 5-year period of observation beginning with
1971–1975. This was followed by age-period-cohort analysis, with
ten 5-year age groups (40–44 to 85–89 years), six 5-year periods of
observation (1971–1975 to 1996–2000) and 15 approximate birth
cohorts, represented by central years of birth from 1886 to 1956.
Poisson regression of the incidence on age, period and cohort
was performed. To estimate the separate effects of age (A),
calendar period (P) and birth cohort (C) on the incidence trend, a
series of models were fitted sequentially, using the methods
described by Clayton and Schifflers (1987a,b). The first model
represented the null hypothesis of an age effect with no temporal
variation, while the second model included effects of age and a
regular drift, a smooth trend in incidence which could be
attributable to either period or cohort influences. Subsequently,
age-period (AP), age-cohort (AC) and age-period-cohort (APC)
models were fitted. Models were compared using deviance w
2 tests.
Although the parameters from the APC model cannot be
interpreted due to unidentifiability, the related significance test
remains appropriate.
The analysis was repeated restricted to 1971 to 1990, before PSA
testing was introduced. The best fitting model was used to predict
incidence from 1991 to 2000. The number of predicted cancer cases
by age group was calculated and compared to the observed.
Analysis was performed using STATA 7.0.
RESULTS
Between 1971 and 2000, 22418 men of mean age (s.d.) 74 (8. 5)
years with newly diagnosed prostate cancer were registered in
NSC. Table 1 shows the incidence rates of registered prostate
cancer in NSC by age and calendar period. The corresponding
numbers of cases and person-years are available from the authors.
The approximate birth cohorts can be identified as diagonals of
the table, descending from left to right. The increase over time
was most marked for ages 50–69. The variable increase in the
incidence rates over time by age suggests that there may be cohort
effects.
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yThe age-standardised rates increased from 32/100000 men-years
in 1971 to 89/100000 men-years in 2000, an almost threefold
increase. In 1991, the age-standardised incidence rate was 57/
100000 men-years. Thus, a similar change was observed in the last
10 years to that observed for the first 20 years.
Table 2 shows the relative risks (RR) for period adjusted for age
and cohort adjusted for age (AP and AC models). Compared to the
period 1971–1975, the age-adjusted relative risk of prostate cancer
registration increased to 2.30 (95% CI 2.17–2.43) for the period
1996–2000. Compared to the 1886 birth cohort, the RR increased
to 14.16 (95% 3.55–56.55) for the 1956 birth cohort. From the
table, one can see an approximate 15% increase in incidence per
successive cohort up to birth year 1921, and a 30–40% increase per
successive cohort from birth years 1926 to 1946. The more recent
periods and/or the younger birth cohorts had increased incidence
of prostate cancer.
The ‘drift’ parameter of Clayton and Schifflers (1987a), a trend
in incidence which could be interpreted as either a period or
cohort effect, was highly significant, a 19% increase in incidence
per 5-year period or birth cohort (RR¼1.19, 95%CI 1.17–1.20).
The effect of cohort adjusted for age and drift was strongly
statistically significant (Po0.001). The period effect was not
significant after adjustment for age and drift (P¼0.1). The age-
period-cohort analyses of prostate cancer thus indicated a stronger
dependency on cohort than on period, but the full APC model
provided the best fit to the data.
Restricting the analysis to the period 1971–1990, the effects of
period adjusted for age and drift (P40.1) and cohort adjusted for
age and drift (P40.1) were not significant. This indicated that a
single trend of increasing risk (with time or cohort) was sufficient
to model changes in incidence. The drift parameter in the 1971–
1990 data indicated a 16% increase in incidence per 5-year period
or birth cohort (RR¼1.16, 95% CI 1.14–1.19).
To assess whether the advent of PSA testing in 1991 was
accompanied by a change in the incidence trend, we used the 16%
drift parameter from the data up to 1990 to predict incidence from
1991 to 2000. This was then compared with the observed incidence.
Observed and predicted numbers are shown in Table 3. The
prediction underestimated the 1991–2000 incidence by around 6%
(Po0.001) (Figure 1).
DISCUSSION
This study shows that the incidence of prostate cancer in NSC has
been increasing from 1971 and that this increase has been
accelerating in recent years. Incidence trends of 1971–2000 show
cohort effects. The number of cases since 1991 exceeds by 6%
the number predicted from pre-1991 trends. The fact that actual
incidence was 6% higher than predicted suggests that changes in
risk or in diagnostic practice took place specifically in the 1990’s
leading to a larger number of diagnosed cases (585 extra cases).
The observed increases in incidence in NSC are similar to the
trends in England and Wales (Majeed et al, 2000; Quinn et al,
2001). Increases in the incidence before the introduction of PSA
testing have been reported in other European countries (Gronberg
et al, 1994; Harvei et al, 1996; Moller, 2001) and the USA (Potosky
et al, 1990).
Age-period-cohort modelling using all the data from 1971 to
2000 indicated that cohort effects were taking place, that is,
changes over time were not happening uniformly across the age
range. Increasing incidence was particularly pronounced for the
birth cohorts from 1926 to 1946 and for the 50–69 age groups in
the 1990s.
To our knowledge, there are no previous reports of APC
modelling of prostate cancer incidence in the UK. A study from
Table 1 Incidence of registered prostate cancer per 100000 men-years by age group and period of diagnosis, NSC, 1971–2000
Period of diagnosis
Age group 1971–1975 1976–1980 1981–1985 1986–1990 1991–1995 1996–2000
4 0 – 4 4 1000 11
4 5 – 4 9 2123 23
5 0 – 5 4 8688 1 4 2 3
5 5 – 5 9 2 32 93 43 5 4 67 6
60–64 48 75 89 92 119 177
65–69 120 151 171 189 267 371
70–74 236 255 323 365 432 525
75–79 375 437 469 548 692 734
80–84 445 527 566 807 934 847
85–89 629 735 707 897 1088 1004
Crude rate 83 106 128 153 191 223
Table 2 Relative risks (RR) and 95% confidence intervals (CI) for the
period and cohort effects adjusted for age, NSC, 1971–2000
RR 95% CI
Period
1971–1975 Reference — —
1976–1980 1.19 1.11 1.27
1981–1985 1.35 1.27 1.45
1986–1990 1.60 1.51 1.71
1991–1995 2.00 1.89 2.12
1996–2000 2.30 2.17 2.43
Cohort (central birth year)
1886 Reference — —
1891 1.03 0.83 1.28
1896 1.16 0.95 1.42
1901 1.34 1.10 1.63
1906 1.58 1.30 1.92
1911 1.80 1.49 2.18
1916 2.06 1.70 2.50
1921 2.42 1.99 2.94
1926 3.06 2.51 3.73
1931 4.16 3.40 5.09
1936 5.25 4.24 6.51
1941 7.58 5.94 9.69
1946 10.47 7.53 14.55
1951 8.72 4.35 17.50
1956 14.16 3.55 56.55
‘Drift’, RR per 5 years 1.19 1.17 1.20
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yDenmark (Moller, 2001) from 1943 to 1996 indicated a stronger
dependency on period than on birth cohort. An APC analysis from
five French administrative areas, covered by population-based
registry, from 1982 to 1995 showed period effects and a small but
significant cohort effect (Chirpaz et al, 2002).
If the difference between observed and predicted number of
cases was due to a new detection modality, such as PSA testing,
then we might expect the effect of this detection modality to be
larger than 6% especially after 1995. The apparent gap remained
6% for both periods of 1991–1995 and 1996–2000. This may be
because the increase in PSA testing was compensated for by a
reduction in detection from transurethral resection of the prostate
(TURP). Age-specific patterns in the increased use of PSA and
decreased use of TURP may also be responsible for the greater
increase in incidence in those aged under 70 years. Our companion
paper with local data on individual exposure to PSA testing also
addresses the age issue (Pashayan et al, 2006).
It should be noted that while the excess in 1991–2000 is
significant and almost certainly a real phenomenon, and probably
largely due to increased availability of PSA testing, it is modest.
Further quantification of excess incidence due to PSA testing is
needed.
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Table 3 Observed and expected number of cases of prostate cancer in
NSC, periods 1991–1995 and 1996–2000 by age group, based on trends
for the period 1971–1990
Observed Expected
SE
(expected) Observed – expected
1991–1995
40–44 2 2 0.45 0
45–49 7 11 0.21  4
50–54 42 31 0.12 11
55–59 122 117 0.06 5
60–64 305 279 0.04 26
65–69 650 553 0.03 97
70–74 937 919 0.03 18
75–79 1003 946 0.03 57
80–84 881 805 0.03 76
85–89 414 403 0.04 11
Sub total 4363 4067 296
1996–2000
40–44 3 2 0.448 1
45–49 10 13 0.211  3
50–54 87 46 0.118 41
55–59 224 150 0.066 74
60–64 474 341 0.049 133
65–69 922 656 0.041 266
70–74 1146 1076 0.038 70
75–79 1264 1308 0.037  44
80–84 819 960 0.039  141
85–89 476 584 0.049  108
Sub total 5425 5136 289























Figure 1 Expected risk of prostate cancer 1976–2000, relative to rates
in 1971–1975, estimated using pre-1990 data, compared with the
observed relative risk after 1990.
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